{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:02:55Z","timestamp":1789588975788,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>This report describes a case of a male infant diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who was prescribed favipiravir therapy. The mother noticed a discoloration of the child's eyes within 18\u2005h of therapy, and the cornea returned to normal color within 5 days of medication cessation. This case report highlights the need for monitoring of favipiravir therapy in children due to the potential side effect of corneal discoloration, which has not yet had its long-term effects identified.<\/jats:p>","DOI":"10.3389\/fped.2023.1154814","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:40:10Z","timestamp":1681879210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case report: Favipiravir-induced bluish corneal discoloration in infant with COVID-19"],"prefix":"10.3389","volume":"11","author":[{"given":"Paveewan","family":"Jiravisitkul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraiorn","family":"Thonginnetra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintra","family":"Wongvisavavit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12887-022-03624-4","article-title":"A systematic review and meta-analysis of the epidemiological characteristics of COVID-19 in children","volume":"22","author":"Vosoughi","year":"2022","journal-title":"BMC Pediatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/jmv.27517","article-title":"Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: strategies, benefits, and challenges","volume":"94","author":"Wang","year":"2022","journal-title":"J Med Virol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1015355","DOI":"10.3389\/fimmu.2022.1015355","article-title":"Oral GS-441524 derivatives: next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"926507","DOI":"10.3389\/fphar.2022.926507","article-title":"Bioactive natural products in COVID-19 therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3390\/biomedicines9060689","article-title":"Natural products, alone or in combination with fda-approved drugs, to treat COVID-19 and lung cancer","volume":"9","author":"Yang","year":"2021","journal-title":"Biomedicines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.jep.2021.113869","article-title":"Chinese herbal medicine: fighting SARS-CoV-2 infection on all fronts","volume":"270","author":"Wang","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"B8","year":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jiac.2022.10.008","article-title":"Favipiravir for symptomatic COVID-19: a nationwide observational cohort study","volume":"29","author":"Doi","year":"2023","journal-title":"J Infect Chemother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.4103\/ijo.IJO_1023_21","article-title":"An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19","volume":"69","author":"Raiturcar","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: a new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med J Armed Forces India"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciac712","article-title":"Favipiravir in patients with early mild-to-moderate COVID-19: a randomized controlled trial","volume":"76","author":"Golan","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijid.2022.04.035","article-title":"The efficacy and adverse effects of favipiravir on patients with COVID-19: a systematic review and meta-analysis of published clinical trials and observational studies","volume":"120","author":"Hung","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-021-01610-3","article-title":"Fluorescence of ocular surface in a COVID-19 patient after favipiravir treatment: a case report","volume":"18","author":"Doran","year":"2021","journal-title":"Virol J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e14740","DOI":"10.1111\/dth.14740","article-title":"Fluorescence of nails and hair on wood\u2019s lamp examination in COVID pandemic; undefined effect of favipiravir in humans","volume":"34","author":"Kay\u0131ran","year":"2021","journal-title":"Dermatol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"119241","DOI":"10.1016\/j.saa.2020.119241","article-title":"Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: application to spiked human plasma","volume":"249","author":"Megahed","year":"2021","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1154814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:40:12Z","timestamp":1681879212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1154814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":17,"alternative-id":["10.3389\/fped.2023.1154814"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1154814","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"article-number":"1154814"}}